At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ASND Ascendis Pharma A/S
Post-Mkt 01-13 18:31:10 EST
215.05
+6.29
+3.01%
盘后215.05
+0.000.00%
16:15 EST
High221.75Low206.00Vol1.36M
Open208.00D1 Closing208.76Amplitude7.54%
Mkt Cap13.27BTradable Cap12.92BTotal Shares61.70M
T/O292.61MT/O Rate2.27%Tradable Shares60.08M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Ascendis Pharma price target raised to $246 from $242 at BofA
TIPRANKS  ·  01-12 20:37
Ascendis Pharma price target raised to $246 from $242 at BofA
Ascendis Pharma Plans $120 Million Share Repurchase Program In 2026
Reuters  ·  01-10
Ascendis Pharma Plans $120 Million Share Repurchase Program In 2026
Ascendis Pharma A/S outlines strategy to expand rare disease portfolio and target blockbuster revenues
Reuters  ·  01-10
Ascendis Pharma A/S outlines strategy to expand rare disease portfolio and target blockbuster revenues
Ascendis Pharma Announces 2026 Strategic Roadmap Including Global Commercial Expansion, Anticipated Third TransCon Product Approval, Advancing R&D Pipeline, and $120 Million Share Repurchase Program
Reuters  ·  01-10
Ascendis Pharma Announces 2026 Strategic Roadmap Including Global Commercial Expansion, Anticipated Third TransCon Product Approval, Advancing R&D Pipeline, and $120 Million Share Repurchase Program
Wedbush Raises Ascendis Pharma Price Target to $240 From $220, Maintains Outperform Rating
MT Newswires Live  ·  01-10
Wedbush Raises Ascendis Pharma Price Target to $240 From $220, Maintains Outperform Rating
Ascendis Pharma a/S : Wells Fargo Raises Target Price to $322 From $297
THOMSON REUTERS  ·  01-09
Ascendis Pharma a/S : Wells Fargo Raises Target Price to $322 From $297
Ascendis Pharma A/S Releases Data on TransCon CNP and TransCon hGH Combination Therapy in Achondroplasia
Reuters  ·  01-09
Ascendis Pharma A/S Releases Data on TransCon CNP and TransCon hGH Combination Therapy in Achondroplasia
Ascendis Pharma announces topline results from Week 52 of COACH trial
TIPRANKS  ·  01-09
Ascendis Pharma announces topline results from Week 52 of COACH trial
Ascendis Pharma Reports Positive 52-Week Results from COACH Trial in Pediatric Achondroplasia
Reuters  ·  01-09
Ascendis Pharma Reports Positive 52-Week Results from COACH Trial in Pediatric Achondroplasia
RBC Raises Price Target on Ascendis Pharma to $245 From $240, Keeps Outperform, Speculative Risk
MT Newswires Live  ·  01-08
RBC Raises Price Target on Ascendis Pharma to $245 From $240, Keeps Outperform, Speculative Risk
European Equities Traded in the US as American Depositary Receipts Little Changed in Friday Trading; Gains 2% for Week
MT Newswires Live  ·  2025-12-27
European Equities Traded in the US as American Depositary Receipts Little Changed in Friday Trading; Gains 2% for Week
European Equities Traded in the US as American Depositary Receipts Track Higher in Thursday Trading
MT Newswires Live  ·  2025-12-19
European Equities Traded in the US as American Depositary Receipts Track Higher in Thursday Trading
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading; Shares Still Up This Week
MT Newswires Live  ·  2025-12-13
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading; Shares Still Up This Week
Monolithic Power, Ascendis Pharma And More: CNBC's 'Final Trades'
Benzinga_recent_news  ·  2025-12-09
Monolithic Power, Ascendis Pharma And More: CNBC's 'Final Trades'
Biotech Is Healthier Than Investors Think -- Barron's
Dow Jones  ·  2025-12-06
Biotech Is Healthier Than Investors Think -- Barron's
The Biotech Industry Is Healthier Than Investors Think. These Are the Stocks to Watch. -- Barrons.com
Dow Jones  ·  2025-12-05
The Biotech Industry Is Healthier Than Investors Think. These Are the Stocks to Watch. -- Barrons.com
Ascendis Pharma Hit By FDA Delay As TransCon CNP Decision Slips To 2026
Benzinga  ·  2025-11-28
Ascendis Pharma Hit By FDA Delay As TransCon CNP Decision Slips To 2026
European Equities Traded in the US as American Depositary Receipts Surge in Wednesday Trading
MT Newswires Live  ·  2025-11-27
European Equities Traded in the US as American Depositary Receipts Surge in Wednesday Trading
Stifel Nicolaus Remains a Buy on Ascendis Pharma (ASND)
TIPRANKS  ·  2025-11-26
Stifel Nicolaus Remains a Buy on Ascendis Pharma (ASND)
Ascendis Pharma (ASND) Receives a Buy from Wells Fargo
TIPRANKS  ·  2025-11-26
Ascendis Pharma (ASND) Receives a Buy from Wells Fargo

Introduction

Company Name.
Ascendis Pharma A/S
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia. In addition, it is developing TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/? for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Issue price:
--